Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase

Anand Pathak, Federica Del Monte, Wen Zhao, Jo El Schultz, John N. Lorenz, Ilona Bodi, Doug Weiser, Harvey Hahn, Andrew N. Carr, Faisal Syed, Nirmala Mavila, Leena Jha, Jiang Qian, Yehia Marreez, Guoli Chen, Dennis W. McGraw, E. Kevin Heist, J. Luis Guerrero, Anna A. DePaoli-Roach, Roger J. HajjarEvangelia G. Kranias

Research output: Contribution to journalArticle

173 Citations (Scopus)

Abstract

Abnormal calcium cycling, characteristic of experimental and human heart failure, is associated with impaired sarcoplasmic reticulum calcium uptake activity. This reflects decreases in the cAMP-pathway signaling and increases in type 1 phosphatase activity. The increased protein phosphatase 1 activity is partially due to dephosphorylation and inactivation of its inhibitor-1, promoting dephosphorylation of phospholamban and inhibition of the sarcoplasmic reticulum calcium-pump. Indeed, cardiac-specific expression of a constitutively active inhibitor-1 results in selective enhancement of phospholamban phosphorylation and augmented cardiac contractility at the cellular and intact animal levels. Furthermore, the β-adrenergic response is enhanced in the transgenic hearts compared with wild types. On aortic constriction, the hypercontractile cardiac function is maintained, hypertrophy is attenuated and there is no decompensation in the transgenics compared with wild-type controls. Notably, acute adenoviral gene delivery of the active inhibitor-1, completely restores function and partially reverses remodeling, including normalization of the hyperactivated p38, in the setting of pre-existing heart failure. Thus, the inhibitor 1 of the type 1 phosphatase may represent an attractive new therapeutic target.

Original languageEnglish (US)
Pages (from-to)756-766
Number of pages11
JournalCirculation research
Volume96
Issue number7
DOIs
StatePublished - Apr 15 2005

Fingerprint

Phosphoprotein Phosphatases
Heart Failure
Sarcoplasmic Reticulum
Calcium
Phosphoric Monoester Hydrolases
Protein Phosphatase 1
Constriction
Adrenergic Agents
Hypertrophy
Phosphorylation
Genes
phospholamban
Therapeutics

All Science Journal Classification (ASJC) codes

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Pathak, A., Del Monte, F., Zhao, W., Schultz, J. E., Lorenz, J. N., Bodi, I., ... Kranias, E. G. (2005). Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase. Circulation research, 96(7), 756-766. https://doi.org/10.1161/01.RES.0000161256.85833.fa
Pathak, Anand ; Del Monte, Federica ; Zhao, Wen ; Schultz, Jo El ; Lorenz, John N. ; Bodi, Ilona ; Weiser, Doug ; Hahn, Harvey ; Carr, Andrew N. ; Syed, Faisal ; Mavila, Nirmala ; Jha, Leena ; Qian, Jiang ; Marreez, Yehia ; Chen, Guoli ; McGraw, Dennis W. ; Heist, E. Kevin ; Guerrero, J. Luis ; DePaoli-Roach, Anna A. ; Hajjar, Roger J. ; Kranias, Evangelia G. / Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase. In: Circulation research. 2005 ; Vol. 96, No. 7. pp. 756-766.
@article{f7e13cdf8c77481380303c7bfde2003a,
title = "Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase",
abstract = "Abnormal calcium cycling, characteristic of experimental and human heart failure, is associated with impaired sarcoplasmic reticulum calcium uptake activity. This reflects decreases in the cAMP-pathway signaling and increases in type 1 phosphatase activity. The increased protein phosphatase 1 activity is partially due to dephosphorylation and inactivation of its inhibitor-1, promoting dephosphorylation of phospholamban and inhibition of the sarcoplasmic reticulum calcium-pump. Indeed, cardiac-specific expression of a constitutively active inhibitor-1 results in selective enhancement of phospholamban phosphorylation and augmented cardiac contractility at the cellular and intact animal levels. Furthermore, the β-adrenergic response is enhanced in the transgenic hearts compared with wild types. On aortic constriction, the hypercontractile cardiac function is maintained, hypertrophy is attenuated and there is no decompensation in the transgenics compared with wild-type controls. Notably, acute adenoviral gene delivery of the active inhibitor-1, completely restores function and partially reverses remodeling, including normalization of the hyperactivated p38, in the setting of pre-existing heart failure. Thus, the inhibitor 1 of the type 1 phosphatase may represent an attractive new therapeutic target.",
author = "Anand Pathak and {Del Monte}, Federica and Wen Zhao and Schultz, {Jo El} and Lorenz, {John N.} and Ilona Bodi and Doug Weiser and Harvey Hahn and Carr, {Andrew N.} and Faisal Syed and Nirmala Mavila and Leena Jha and Jiang Qian and Yehia Marreez and Guoli Chen and McGraw, {Dennis W.} and Heist, {E. Kevin} and Guerrero, {J. Luis} and DePaoli-Roach, {Anna A.} and Hajjar, {Roger J.} and Kranias, {Evangelia G.}",
year = "2005",
month = "4",
day = "15",
doi = "10.1161/01.RES.0000161256.85833.fa",
language = "English (US)",
volume = "96",
pages = "756--766",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

Pathak, A, Del Monte, F, Zhao, W, Schultz, JE, Lorenz, JN, Bodi, I, Weiser, D, Hahn, H, Carr, AN, Syed, F, Mavila, N, Jha, L, Qian, J, Marreez, Y, Chen, G, McGraw, DW, Heist, EK, Guerrero, JL, DePaoli-Roach, AA, Hajjar, RJ & Kranias, EG 2005, 'Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase', Circulation research, vol. 96, no. 7, pp. 756-766. https://doi.org/10.1161/01.RES.0000161256.85833.fa

Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase. / Pathak, Anand; Del Monte, Federica; Zhao, Wen; Schultz, Jo El; Lorenz, John N.; Bodi, Ilona; Weiser, Doug; Hahn, Harvey; Carr, Andrew N.; Syed, Faisal; Mavila, Nirmala; Jha, Leena; Qian, Jiang; Marreez, Yehia; Chen, Guoli; McGraw, Dennis W.; Heist, E. Kevin; Guerrero, J. Luis; DePaoli-Roach, Anna A.; Hajjar, Roger J.; Kranias, Evangelia G.

In: Circulation research, Vol. 96, No. 7, 15.04.2005, p. 756-766.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase

AU - Pathak, Anand

AU - Del Monte, Federica

AU - Zhao, Wen

AU - Schultz, Jo El

AU - Lorenz, John N.

AU - Bodi, Ilona

AU - Weiser, Doug

AU - Hahn, Harvey

AU - Carr, Andrew N.

AU - Syed, Faisal

AU - Mavila, Nirmala

AU - Jha, Leena

AU - Qian, Jiang

AU - Marreez, Yehia

AU - Chen, Guoli

AU - McGraw, Dennis W.

AU - Heist, E. Kevin

AU - Guerrero, J. Luis

AU - DePaoli-Roach, Anna A.

AU - Hajjar, Roger J.

AU - Kranias, Evangelia G.

PY - 2005/4/15

Y1 - 2005/4/15

N2 - Abnormal calcium cycling, characteristic of experimental and human heart failure, is associated with impaired sarcoplasmic reticulum calcium uptake activity. This reflects decreases in the cAMP-pathway signaling and increases in type 1 phosphatase activity. The increased protein phosphatase 1 activity is partially due to dephosphorylation and inactivation of its inhibitor-1, promoting dephosphorylation of phospholamban and inhibition of the sarcoplasmic reticulum calcium-pump. Indeed, cardiac-specific expression of a constitutively active inhibitor-1 results in selective enhancement of phospholamban phosphorylation and augmented cardiac contractility at the cellular and intact animal levels. Furthermore, the β-adrenergic response is enhanced in the transgenic hearts compared with wild types. On aortic constriction, the hypercontractile cardiac function is maintained, hypertrophy is attenuated and there is no decompensation in the transgenics compared with wild-type controls. Notably, acute adenoviral gene delivery of the active inhibitor-1, completely restores function and partially reverses remodeling, including normalization of the hyperactivated p38, in the setting of pre-existing heart failure. Thus, the inhibitor 1 of the type 1 phosphatase may represent an attractive new therapeutic target.

AB - Abnormal calcium cycling, characteristic of experimental and human heart failure, is associated with impaired sarcoplasmic reticulum calcium uptake activity. This reflects decreases in the cAMP-pathway signaling and increases in type 1 phosphatase activity. The increased protein phosphatase 1 activity is partially due to dephosphorylation and inactivation of its inhibitor-1, promoting dephosphorylation of phospholamban and inhibition of the sarcoplasmic reticulum calcium-pump. Indeed, cardiac-specific expression of a constitutively active inhibitor-1 results in selective enhancement of phospholamban phosphorylation and augmented cardiac contractility at the cellular and intact animal levels. Furthermore, the β-adrenergic response is enhanced in the transgenic hearts compared with wild types. On aortic constriction, the hypercontractile cardiac function is maintained, hypertrophy is attenuated and there is no decompensation in the transgenics compared with wild-type controls. Notably, acute adenoviral gene delivery of the active inhibitor-1, completely restores function and partially reverses remodeling, including normalization of the hyperactivated p38, in the setting of pre-existing heart failure. Thus, the inhibitor 1 of the type 1 phosphatase may represent an attractive new therapeutic target.

UR - http://www.scopus.com/inward/record.url?scp=20244377242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244377242&partnerID=8YFLogxK

U2 - 10.1161/01.RES.0000161256.85833.fa

DO - 10.1161/01.RES.0000161256.85833.fa

M3 - Article

C2 - 15746443

AN - SCOPUS:20244377242

VL - 96

SP - 756

EP - 766

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 7

ER -